Social Anxiety Disorder Clinical Trial
Official title:
Brief Intervention to Reduce Fear of Public Speaking
Verified date | May 2023 |
Source | New York State Psychiatric Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study will test the efficacy of propranolol or placebo, administered after retrieval of a previously acquired public speaking fear, in reducing fear and avoidance of public speaking.
Status | Terminated |
Enrollment | 6 |
Est. completion date | October 30, 2020 |
Est. primary completion date | October 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - 18-60 years of age at the time of consent - Principal Diagnosis of Social Anxiety Disorder, Performance only type - Has clinically significant fear of public speaking - Physically healthy - If female, non-pregnant and not nursing - Off all psychotropic drug for at least 4 weeks - A level of understanding sufficient to provide written informed consent to all required study tests and procedures. Exclusion Criteria: - History of other serious psychiatric disorder - Current Major Depressive Disorder - Presence of developmental disorder or intellectual disability - SAD patients with SAD not of the performance only type - Women who are pregnant or nursing - Current use of psychiatric medication - Current substance use disorder - Persons planning to start another treatment during the study period. - Any significant medical condition that might increase the risk or participation (e.g., seizure disorder, respiratory disorders [e.g., bronchial asthma], cardiovascular disease [e.g., congestive heart failure, heart arrhythmias, sinus bradycardia and greater than first degree block ], low blood pressure [ < 90/60], diabetes, liver or kidney disorders) - Use of medications that might negatively interact with propranolol (e.g., ACE inhibitors; catecholamine depleting drugs, such as reserpine; calcium channel blockers; digitalis glycosides; haloperidol; chlorpromazine; aluminum hydroxide gel; phenytoin; phenobarbitone; rifampin; antipyrine; lidocaine; cimetidine; theophylline) |
Country | Name | City | State |
---|---|---|---|
United States | New York State Psychiatric Institute, 1051 Riverside Drive | New York | New York |
Lead Sponsor | Collaborator |
---|---|
New York State Psychiatric Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Personal Report of Confidence as a Speaker | total score on this self report measure of fear of public speaking. Scored from 0-30, with higher scores indicating better outcome | 2 weeks | |
Secondary | Behavioral Avoidance Task | Up to 5 sequential public speaking challenges, specifically designed for each step to be of increasing difficulty for the individual. Each step is considered completed if subject agrees to try speaking, and speaks for 1 minute. Score is total number of completed steps (0-5) on this 5-step task, with 5 being best | 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06274112 -
Using TMS to Understand Neural Processes of Social Motivation
|
N/A | |
Completed |
NCT02554929 -
Treatment of Social Anxiety Disorder and Selective Mutism
|
N/A | |
Completed |
NCT00684541 -
Interpretation Modification Program for Social Phobia
|
N/A | |
Completed |
NCT00684320 -
Attention Disengagement Training for Social Phobia
|
N/A | |
Completed |
NCT03247075 -
Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT
|
N/A | |
Completed |
NCT02811458 -
Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders
|
N/A | |
Withdrawn |
NCT04622930 -
Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD)
|
N/A | |
Active, not recruiting |
NCT05018312 -
Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety
|
N/A | |
Active, not recruiting |
NCT05124639 -
Clinical Trial of a Group Self-management Support Program for Anxiety Disorders
|
N/A | |
Completed |
NCT05858294 -
The Safety, Acceptability and Efficacy of Alena
|
N/A | |
Active, not recruiting |
NCT05600114 -
Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
|
Phase 2 | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Not yet recruiting |
NCT02924610 -
Brief Intervention to Reduce Fear
|
Phase 4 | |
Active, not recruiting |
NCT02592564 -
Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder
|
N/A | |
Recruiting |
NCT02305537 -
Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment
|
N/A | |
Terminated |
NCT03764644 -
Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders
|
N/A | |
Unknown status |
NCT01712321 -
Study of Vilazodone to Treat Social Anxiety Disorder
|
N/A | |
Completed |
NCT01320800 -
CBT for Social Anxiety Disorder Delivered by School Counselors
|
Phase 2 | |
Completed |
NCT00485888 -
Flushing in Social Anxiety Disorder on Cipralex
|
Phase 2 | |
Completed |
NCT00872820 -
Examining Long-Term Effects and Neural Mediators of Behavioral Treatments for Social Anxiety Disorder
|
N/A |